Advertisement

Acivicin: A new antimetabolite

  • Robert H. Earhart
Part of the Cancer Treatment and Research book series (CTAR, volume 36)

Abstract

Acivicin is an L-glutamine antagonist which underwent phase II clinical efficacy evaluation as an anticancer drug in 1985–1986. The biochemical pharmacology of this agent is unique among antimetabolites and offers several interesting possibilities for combination therapy with agents whose activity can be potentiated by acivicin, with agents which can interfere with cellular resistance to acivicin, and with agents which can lessen the dose-limiting toxicity of acivicin. This review will cover some of the experimental background of current clinical research involving acivicin, will relate clinical findings to the preclinical pharmacology of the drug, and will suggest some new directions for both clinical and preclinical research.

Keywords

Maximum Tolerate Dose Biochemical Pharmacology Large Neutral Amino Acid Ibotenic Acid Lewis Lung Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Neil GL, Berger AE, Bhuyan BK, Blowers CL, and Kuenzel SL: Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Advances in Enzyme Regulation 17:375–398, 1979.CrossRefGoogle Scholar
  2. 2.
    Earhart RH and Neil GL: Acivicin in 1985. Advances in Enzyme Regulation 24:179–205, 1986.CrossRefGoogle Scholar
  3. 3.
    Hanka LJ and Dietz A: U-42, 126, a new antimetabolite antibiotic: Production, biological activity, and taxonomy of the producing microorganism. Antimicrobial Agents Chemother 3:425–431, 1973.Google Scholar
  4. 4.
    Hanka LJ, Martin DG, and Neil GL: A new antitumor antimetabolite, (aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): Antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo. Cancer Chemother Rep 57:141–148, 1973.PubMedGoogle Scholar
  5. 5.
    Martin DG, Duchamp DJ, and Chidester CG: The isolation, structure, and absolute configuration of U-42, 126, a novel antitumor antibiotic. Tetrahedron Lett 27:2549–2552, 1973.CrossRefGoogle Scholar
  6. 6.
    Jayaram HN, Cooney DA, Ryan JA, Neil G, Dion RL, and Bono VH: L-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): A new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep 59:481— 491, 1975.PubMedGoogle Scholar
  7. 7.
    Neil GL, Berger AE, McPartland RP, Grindey GB, and Bloch A: Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (a-S,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Cancer Res 39:852–856, 1979.PubMedGoogle Scholar
  8. 8.
    Sebolt JS, Aoki T, Eble JN, Glover JL, and Weber G: Inactivation by acivicin of carbamoyl-phosphate synthetase II of human colon carcinoma. Biochemical Pharmacology 34:97–100, 1984.CrossRefGoogle Scholar
  9. 9.
    Elliott WL and Weber G: In vivo inactivation of formylglycinamine ribonucleotide synthetase in rat hepatoma. Biochemical Pharmacology 34:243–248, 1984.CrossRefGoogle Scholar
  10. 10.
    Allen L, Meek R, and Yunis A: The inhibition of 7-glutamyl transpeptidase from human pancreatic carcinoma cells by (aS,5S-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501). Res Comm Chem Path Pharmacol 27:175–182, 1980.Google Scholar
  11. 11.
    Allen LM, Corrigan MV, and Meinking T: Interaction of AT-125, (aS,5S)-a-amino-3-chloro-4,5-dihydro-isoxazoleacetic acid, with bovine kidney 7-glutamyl transpeptidase. Chem-Biol Interactions 33:361–365, 1981.CrossRefGoogle Scholar
  12. 12.
    Dass PD and Welbourne TC: Effect of AT-125 on in situ renal 7-glutamyl-transferase activity. FEBS Letters 144:21–24, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Curthoys NP: Role of 7-glutamyltranspeptidase in the renal metabolism of glutathione. Mineral Electrolyte Metab 9:236–245, 1983.Google Scholar
  14. 14.
    Zunino F, Tofanetti O, Besati A, Cavalletti E, and Savi G: Protective effect of reduced glutathione against cis-dichlorodiammine platinum (Il)-induced nephrotoxicity and lethal toxicity. Tumori 69:105–111, 1983.PubMedGoogle Scholar
  15. 15.
    Meister A and Griffith OW: Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione: Possible chemotherapeutic implications. Cancer Treat Rep 63:1115–1121, 1979.PubMedGoogle Scholar
  16. 16.
    Arrick BA and Nathan CF: Glutathione metabolism as a determinant of therapeutic efficacy: A review. Cancer Res 44:4224–4232, 1984.PubMedGoogle Scholar
  17. 17.
    Elfarra AA and Anders MW: Renal processing of glutathione conjugates. Role in nephrotoxicity. Biochem Pharmacol 33:3729–3732, 1984.PubMedCrossRefGoogle Scholar
  18. 18.
    Thornthwaite JT and Allen LM: The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry. Res Comm Chem Path Pharmacol 29:393–396, 1980.Google Scholar
  19. 19.
    Meek RA, Clubb KJ, Allen LM, and Yunis AA: Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by l-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, acivicin (NSC 163501). Cancer Res 41:4547–4553, 1981.Google Scholar
  20. 20.
    Clauw DJ, Wheeler RH, Hudson JL, and Lovett EJ: In vitro cytokinetic and cytotoxic effects of AT-125 (acivicin) in Burkitt lymphoma cells. Proc Am Assoc Cancer Res 24:305, 1983.Google Scholar
  21. 21.
    Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, and Neil GL: Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63:473–476, 1979.PubMedGoogle Scholar
  22. 22.
    Poster DS, Bruno S, Penta J, Neil GL, and McGovren JP: Acivicin, an antitumor antibiotic. Cancer Clin Trials 4:327–330, 1981.PubMedGoogle Scholar
  23. 23.
    Houchens DP, Ovejera AA, and Barker AD: The therapy of human tumors in athymic (nude) mice. In: Proc Symp on the Use of Athymic (Nude) Mice in Cancer Research, DP Houchens and AA Ovejera (eds). New York: Gustav Fisher, p 267–280, 1978.Google Scholar
  24. 24.
    McGovren JP, Neil GL, Sem PCC, and Stewart JC: Sex- and age-related mouse toxicity and disposition of the amino acid antitumor agent, acivicin. J Pharm Exp Ther 216:433–440, 1981.Google Scholar
  25. 25.
    Pratt EA, Lancaster C, Adams EG, DeKoning TF, Hanka LJ, and McGovren JP: Toxic and therapeutic effects of continuous acivicin (AT-125) infusion in leukemic mice using the Alzet osmotic minipump. Proc Am Assoc Cancer Res 22:205, 1981.Google Scholar
  26. 26.
    Weiss GR, McGovren JP, Schade D, and Kufe DW: Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer Res 42:3892–3895, 1982.PubMedGoogle Scholar
  27. 27.
    Earhart RH, Koeller JM, Davis TE, Borden EC, McGovren JP, Davis HL, and Tormey DC: Phase I trial and pharmacokinetics of acivicin administered by 72-Iiour infusion. Cancer Treat Rep 67:683–692, 1983.PubMedGoogle Scholar
  28. 28.
    Sridhar KS, Ohnuma T, Chahinian AP, and Holland JF: Phase I study of acivicin in patients with advanced cancer. Cancer Treat Rep 67:701–703, 1983.PubMedGoogle Scholar
  29. 29.
    Murphy WK, Burgess MA, Valdivierso M, and Bodey GP: Phase I evaluation of acivicin (AT-125). Proc Am Soc Clin Oncol 1:23, 1982.Google Scholar
  30. 30.
    Taylor S, Belt RJ, Joseph U, Haas CD, and Hoogstraten B: Phase I evaluation of AT-125 single dose every three weeks. Invest New Drugs 2:311–314, 1984.PubMedCrossRefGoogle Scholar
  31. 31.
    McGrovren JP, Pratt EA, Belt RJ, Taylor SA, Benjamin RS, Ardalan B, and Ohnuma T: Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. Cancer Res 45:4460–4463, 1985.Google Scholar
  32. 32.
    Robins RH, Williams MG, and McGovren JP: Quantitation of antitumor agent acivicin in plasma by gas chromatography with mass spectral detection. J Analyt Chem 57:2046–2049, 1985.CrossRefGoogle Scholar
  33. 33.
    McGovren JP, Stewart JC, Elfring GL, Smith RB, Soares N, Wood JH, Poplack DG, and Von Hoff DD: Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing Phesus monkeys. Cancer Treat Rep 66:1333–1341, 1982.PubMedGoogle Scholar
  34. 34.
    Maroun J, Maksymiuk A, Eisenhauer E, Stewart D, Young V, and Pater J: A phase II trial of acivicin (AT-125, NSC 163501) in metastatic non-small cell lung cancer (NSCLC). A Canadian National Cancer Institute study. Proc Am Soc Clin Oncol 3:218, 1984.Google Scholar
  35. 35.
    Maroun J, Fields AL, Pater JE, Stewart DJ, Cripps C, and Eisenhauer E: Phase II study of acivicin in colorectal carcinoma: A Canadian National Cancer Institute study. Cancer Treat Rep 68:1121–1123, 1984.PubMedGoogle Scholar
  36. 36.
    Adolphson C, Bedikian AY, Stroehlein JR, Carlin DA, Bodey GP, and Hickey RC: Phase II evaluation of acivicin (AT-125; NSC 163501) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1:96, 1982.Google Scholar
  37. 37.
    Fleishman G, Yap H-Y, Murphy WK, and Bodey G: Phase II trial of acivicin in advanced metastatic breast cancer. Cancer Treat Rep 67:843–844, 1983.PubMedGoogle Scholar
  38. 38.
    McGuire WP, Blessing JA, DiSaia PJ, and Buchsbaum HJ: Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. Invest New Drugs 4:49–52, 1986.PubMedGoogle Scholar
  39. 39.
    Von Hoff DD and Clark GM: Dose response curves for anticancer agents against human breast cancer. Clin Pharmacol Therap 37:236–240, 1985.Google Scholar
  40. 40.
    McGrovren JP, Piercey MJ, Einspahr FJ, Tang AH, Schreur PJD, and Williams MG: Studies of the central nervous system (CNS) toxicity of acivicin (NSC 163501). Proc Am Assoc Cancer Res 26:370, 1985.Google Scholar
  41. 41.
    Krogsgaard-Larsen P, Honore T, and Hansen JJ: New class of glutamate agonist structurally related to ibotenic acid. Nature 284:64, 1980.PubMedCrossRefGoogle Scholar
  42. 42.
    Naik SR, Guidotti A, and Costa E: Central GAB A receptor agonists: Comparison of muscimol and baclofen. Neuropharmacology 15:479, 1976.PubMedCrossRefGoogle Scholar
  43. 43.
    Mandel P: Free nucleotides. In: Handbook of Neurochemistry, v 5, part A, A Lajtha (ed). New York: Plenum Press, 249–281, 1971.Google Scholar
  44. 44.
    Fonnum F: Glutamate: A neurotransmitter in mammalian brain. J Neurochem 42:1–11, 1984.PubMedCrossRefGoogle Scholar
  45. 45.
    Bachelard HS: Biochemistry of centrally active amino acids, In: Adv Biochem Psychopharm 29, FV Defeudis and P Mandel (eds). New York: Raven Press, p 475–497, 1981.Google Scholar
  46. 46.
    Hertz L: Functional interactions between neurons and astrocytes 1. Turnover and metabolism of putative amino acid transmitters. Prog Neurobiol 13:277–323, 1979.PubMedCrossRefGoogle Scholar
  47. 47.
    Shank RP and Aprison MH: Present status and significance of the glutamine cycle in neural tissues. Life Sciences 28:837–842, 1981.PubMedCrossRefGoogle Scholar
  48. 48.
    Berl S and Clarke DD: Cerebral glutamine/glutamate interrelationships and metabolic compartmentation. In: Glutamine Metabolism in Mammalian Tissues. D Haussinger and S Sies (eds). Berlin: Spring-Verlag, p 223–234, 1984.Google Scholar
  49. 49.
    Hill KE, Von Hoff DD, and Burk RF: Effect of inhibition of Y-glutamyltranspepitdase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasma. Invest New Drugs 3:31–34, 1985.PubMedCrossRefGoogle Scholar
  50. 50.
    Ohnuma T, Holland JF, Freeman A, and Sinks LF: Biochemical and pharmacological studies with asparaginase in man. Cancer Res 30:2297–2305, 1970.PubMedGoogle Scholar
  51. 51.
    Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallal L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, Murphy ML, and Burchenal JH: Toxicity of E coliL-asparaginase in man. Cancer 25:253–278, 1970.PubMedCrossRefGoogle Scholar
  52. 52.
    Holcenberg JS, Borella LD, Camitta BM, and Ring BJ: Human pharmacology and toxicology of succinylated Acinetobacter glutaminase-asparaginase. Cancer Res 39:3145–3151, 1979.PubMedGoogle Scholar
  53. 53.
    Allen LM and Yunis AA: Cellular transport of the glutamine analog acivicin does not require gamma-glutamyl transpeptidase, ICRS Med Sci 11:125–126, 1983.Google Scholar
  54. 54.
    Jayaram HN, Ardalan B, Deas M, and Johnson RK: Mechanism of resistance of a variant of P388 leukemia to L-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivi-cin). Cancer Res 45:207–212, 1985.PubMedGoogle Scholar
  55. 55.
    James JH and Fischer JE: Transport of neutral amino acids at the blood-brain barrier. Pharmacol 22:1–17, 1981.CrossRefGoogle Scholar
  56. 56.
    Weber G, Prajda N, Lui MS, Denton JE, Aoki T, Sebolt J, Zhen Y, Burt ME, Faderan MA, and Reardon MA: Multienzyme-targeted chemotherapy by acivicin and actinomycin. Adv Enzyme Regulation 20:75–96, 1982.CrossRefGoogle Scholar
  57. 57.
    Holcenberg JS, Lu P, and Tang E: Enhanced effect of L-glutamine antagonist, L-(aS,5S)-α-amino-3-chloro-4,6-dihydro-5-isoxazoleacetic acid (NSC-163501), by Acinetobacter glutaminase-asparaginase. Proc Am Assoc Cancer Res 17:168, 1976.Google Scholar
  58. 58.
    Holcenberg JS: Enhanced effect of an L-glutamine antagonist, L-(αS,5S)-α-amino-3-chloro-4,6-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-1-asparaginase. Cancer Treat Rep 63:1109–1114, 1979.PubMedGoogle Scholar
  59. 59.
    Rosenfeld H and Roberts J: Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-l-norleucine and acivicin in cell culture by glutaminase-asparaginase. Cancer Res 41:1324–1328, 1981.PubMedGoogle Scholar
  60. 60.
    Bhalla K, Nayak R, Deitch A, and Grant S: Synergistic interaction between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Biochemical and cytokinetic considerations. Biochem Pharmacol 33:247–254, 1984.PubMedCrossRefGoogle Scholar
  61. 61.
    Padgett RA, Wahl GM, and Stark GR: Stucture of the gene for CAD, the multifunction protein that initiates UMP synthesis in Syrian hamster cells. Molec Cellular Biol 2:293–301, 1982.Google Scholar
  62. 62.
    Christopherson Rl, Traut TW, and Jones ME: Multienzymatic proteins in mammalian pyrimidine biosynthesis: Channeling of intermediates to avoid futile cycles. Current Topics in Cellular Regulation 18:59–77, 1981.PubMedGoogle Scholar
  63. 63.
    Wahl GM, Vitto L, Padgett RA, and Stark GR: Single-copy and amplified CAD genes in Syrian hamster chromosomes localized by a highly sensitive method for in situ hybridization. Molec Cellular Biol 2:308–319, 1982.Google Scholar
  64. 64.
    Kensler TW, Mutter G, Hankerson JG, Reck LJ, Harley C, Han N, Ardalan B, Cysyk RL, Johnson RK, Jayaram HN, and Cooney DA: Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-l-aspartic acid. Cancer Res 41:894–904, 1981.PubMedGoogle Scholar
  65. 65.
    Loh E and Kufe DW: Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-l-aspartic acid. Cancer Res 41:3419–3423, 1981.PubMedGoogle Scholar
  66. 66.
    Kensler TW, Reck LJ, and Cooney DA: Therapeutic effects of acivicin and N-(phosphonacetyl)-l-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-l-aspartic acid-resistant variant of the Lewis lung carcinoma. Cancer Res 41:905–909, 1981.PubMedGoogle Scholar
  67. 67.
    Ardalan B, Jayaram HN, and Johnson RK: Collateral sensitivity to N-(phosphonacetyl)-l-aspartatic acid in a line of P388 leukemia cells selected for resistance to l-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Cancer Res 43:1598–1601, 1983.PubMedGoogle Scholar
  68. 68.
    Ardalan B and MacDonald JS: Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man. Adv Pharmacol Chemother 17:289–321, 1980.PubMedCrossRefGoogle Scholar
  69. 69.
    Ardalan B and Chandrasekaran B: Biochemical mechanisms for the scheduled synergism of (αS,5S)-α-amino-3-chloro-4,6-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia. Cancer Chemother Pharmacol 15:44–48, 1985.PubMedCrossRefGoogle Scholar
  70. 70.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, and Young CW: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-l-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res 43:2317–2321, 1983.PubMedGoogle Scholar
  71. 71.
    Chabner BA: Cytosine arabinoside. In: Pharmacologic Principles of Cancer Treatment, B Chabner (ed). Philadelphia: W.B. Saunders, p 387–401, 1982.Google Scholar
  72. 72.
    Mills-Yamamoto C, Lauzon GJ, and Paterson ARP: Toxicity of combinations of arabinosyl cytosine and 3-deazauridine toward neoplastic cells in culture. Biochem Pharmacol 27:181–186, 1978.PubMedCrossRefGoogle Scholar
  73. 73.
    Zhen Y, Lui MS, and Weber G: Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43:1616–1619, 1983.PubMedGoogle Scholar
  74. 74.
    Weber G, Lui MS, Sebolt J, and Faderan MA: Molecular targets of antiglutamine therapy with acivicin in cancer cells. In: Glutamine Metabolism in Mammalian Tissues, D Haussin-ger and S Sies (eds). Berlin: Spring-Verlag, p 278–291, 1984.Google Scholar
  75. 75.
    Fischer PH, Pamukcu R, Bittner G, and Willson JKV: Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole. Cancer Res 44:3355–3359, 1984.PubMedGoogle Scholar
  76. 76.
    Kessel D and Hall TC: Effects of persantin on deoxycytidine transport by murine leukemia cells. Biochim Biophys Acta 211:88–94, 1970.PubMedCrossRefGoogle Scholar
  77. 77.
    Paterson ARP, Kolassa N, and Cass CE: Transport of nucleoside drugs in animal cells. Pharmacol Ther 12:515–536, 1981.PubMedCrossRefGoogle Scholar
  78. 78.
    Weber G, Lui MS, Natsumeda Y, Faderan MA, Reardon MA, Emrani J, Eble JN, and Glover JL: Purine enzymic programs of human colon adenocarcinoma. Proc Am Assoc Cancer Res 26:11, 1985.Google Scholar
  79. 79.
    Denton JE, Lui MS, Aoki T, Sebolt J, Takeda E, Eble JN, Glover JL, and Weber G: Enzymology of pyrimidine and carbohydrate metabolism in human colon carciomas. Cancer Res 42:1176–1183, 1982.PubMedGoogle Scholar
  80. 80.
    Willson JVK, Fischer PH, Van Mouwerik TJ, Koeller JM, Trump DL, and Tormey DC: A phase I trial of acivicin and dipyridamole given by concurrent IV infusion. Proc Am Assoc Cancer Res 25:164, 1984.Google Scholar
  81. 81.
    Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes memorial lecture. Cancer Res 43:3466–3492, 1983.PubMedGoogle Scholar
  82. 82.
    Weber G, Lui MS, Natsumeda Y, and Faderan MA: Salvage capacity of hepatoma 3924A and action of dipyridamole. Advances in Enzyme Regulation 21:53–69, 1983.PubMedCrossRefGoogle Scholar
  83. 83.
    Weber G, Natsumeda Y, Lui MS, Faderan MA, Liepnieks JJ, and Elliott WL: Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin. Advances in Enzyme Regulation 22:69–93, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Robert H. Earhart

There are no affiliations available

Personalised recommendations